RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cantabio Pharmaceuticals Stock

Cantabio Pharmaceuticals Net Income 2024

Cantabio Pharmaceuticals Net Income

-2.01 M USD

Ticker

CTBO

ISIN

US13808X2036

WKN

A2PMPJ

In 2024, Cantabio Pharmaceuticals's profit amounted to -2.01 M USD, a 80.89% increase from the -1.11 M USD profit recorded in the previous year.

The Cantabio Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2018-2,011.77
2017-1,112.14
2016-751.33
201578.3
2014-86.85
2013-26.58
2012-10

Cantabio Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cantabio Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cantabio Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cantabio Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cantabio Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cantabio Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cantabio Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cantabio Pharmaceuticals’s growth potential.

Cantabio Pharmaceuticals Revenue, EBIT and net profit per share

DateCantabio Pharmaceuticals RevenueCantabio Pharmaceuticals EBITCantabio Pharmaceuticals Net Income
20180 USD-1.35 M USD-2.01 M USD
20170 USD-1.07 M USD-1.11 M USD
20160 USD-840,930 USD-751,330 USD
20150 USD-29,680 USD78,300 USD
20140 USD-86,850 USD-86,850 USD
20130 USD-26,580 USD-26,580 USD
20120 USD-10,000 USD-10,000 USD

Cantabio Pharmaceuticals stock margins

The Cantabio Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cantabio Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cantabio Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cantabio Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Cantabio Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cantabio Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cantabio Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cantabio Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cantabio Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cantabio Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cantabio Pharmaceuticals Margin History

Cantabio Pharmaceuticals Gross marginCantabio Pharmaceuticals Profit marginCantabio Pharmaceuticals EBIT marginCantabio Pharmaceuticals Profit margin
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Cantabio Pharmaceuticals Aktienanalyse

What does Cantabio Pharmaceuticals do?

Cantabio Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the development of innovative therapies for neurodegenerative diseases. The company was founded in 2009 by Professor Gou-Ping Chen, an expert in protein structures and functions. Cantabio Pharmaceuticals was established specifically to address neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, which are among the largest and most prevalent diseases in the aging population. The business model of Cantabio Pharmaceuticals is based on the development of products that have been developed based on new insights in molecular research and increased understanding of neurodegenerative diseases. By collaborating with universities, research laboratories, and other industry partners, the company employs an innovation strategy to present novel solutions to the public. For its research and products, the company focuses on three main areas: - Drug discovery - the company has a variety of products in the pipeline, from discovery to clinical phases, which are strictly regulated by the FDA. - Protein and antibody manufacturing - the company uses the latest technologies to manipulate proteins to maximize their beneficial effects and optimize their potential therapeutic efficacy. - Diagnostic tools - the company also develops diagnostic tests and analysis tools for the detection of biomarkers to enable faster and more accurate diagnosis. In basic research, the company has discovered a novel class of proteins called Alpha-Synuclein inhibitors. Alpha-Synuclein is a protein that is associated with Parkinson's disease due to its overproduction and accumulation. Through experiments, Cantabio scientists have discovered substances to inhibit or even reduce its production and accumulation. These discoveries have gained significant attention in the scientific community and could contribute to important advances in understanding and overcoming brain pathologies. Cantabio Pharmaceuticals' products include a range of treatments applicable to specific diseases. One of the company's most important products is the novel drug CB2813, which targets the treatment of Alzheimer's and other neurodegenerative diseases. CB2813 represents an innovation in the treatment of Alzheimer's by combating the progression of the disease at the molecular level and strengthening the brain's biochemical protection. Another product of Cantabio Pharmaceuticals is the Alpha-Synuclein inhibitor CNS5874, which is used in Parkinson's disease. Parkinson's disease is characterized by the loss of dopamine receptors and the accumulation of Alpha-Synuclein protein. Administration of CNS5874 can reduce the accumulated Alpha-Synuclein protein in the brain regions significantly affected by the disease and promote improvement in patient behavior. Overall, Cantabio Pharmaceuticals is a leading company in the field of neurodegenerative diseases, focusing on the development of innovative treatment methods. In order to expand its pipeline and improve the available treatment options for patients, the company is constantly developing new products, some of which are already in research and clinical development. Cantabio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Cantabio Pharmaceuticals's Profit Margins

The profit margins of Cantabio Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Cantabio Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Cantabio Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Cantabio Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Cantabio Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Cantabio Pharmaceuticals stock

How much profit has Cantabio Pharmaceuticals made this year?

Cantabio Pharmaceuticals has made -2.01 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 80.89% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Cantabio Pharmaceuticals publish its earnings?

Cantabio Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Cantabio Pharmaceuticals?

The profits of Cantabio Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Cantabio Pharmaceuticals?

You can learn more about the earnings of Cantabio Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Cantabio Pharmaceuticals pay?

Over the past 12 months, Cantabio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cantabio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cantabio Pharmaceuticals?

The current dividend yield of Cantabio Pharmaceuticals is .

When does Cantabio Pharmaceuticals pay dividends?

Cantabio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cantabio Pharmaceuticals?

Cantabio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cantabio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cantabio Pharmaceuticals located?

Cantabio Pharmaceuticals is assigned to the '-' sector.

Wann musste ich die Aktien von Cantabio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cantabio Pharmaceuticals from 11/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did Cantabio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of Cantabio Pharmaceuticals in the year 2023?

In the year 2023, Cantabio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cantabio Pharmaceuticals pay out the dividend?

The dividends of Cantabio Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cantabio Pharmaceuticals

Our stock analysis for Cantabio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cantabio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.